Figure 1. Flow chart of enrolment, randomization, and follow-up. PROM, patient-reported outcome measure
Figure 2. Effect of beta-blocker therapy on symptoms of depression and anxiety. BB, beta-blocker; HADS, Hospital Anxiety and Depression Scale; PHQ-2, Patient Health Questionnaire-2
Figure 3. Subgroup analyses of symptoms of depression and anxiety. The figure shows the between-group difference in change in symptoms from baseline to each follow-up in subgroups of the study population. Positive values are an increase in the beta-blocker (BB) group compared with the no BB group. At baseline, 3450 patients were under 70 years of age, while 1283 were 70 years of age or older. Analyses on metoprolol dose and prior BB only in the BETAMI cohort. Number of patients in the BB arm with dose <50 mg/day is 430, ≥50 mg/day is 595, and ≥100 mg/days 52. In BETAMI, 155 patients had prior BB and 1894 no prior BB. CI, Confidence interval; HADS-A, Hospital Anxiety and Depression Scale anxiety subscale; HADS-D, Hospital Anxiety and Depression Scale depression subscale; LVEF, left ventricular ejection fraction; PHQ-2, Patient Health Questionnaire-2
We only have this paper's title and publication details.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nyen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: